Cargando…
Development and characterisation of a novel glucagon like peptide-1 receptor antibody
AIMS/HYPOTHESIS: Glucagon like peptide-1 (GLP-1) enhances glucose-dependent insulin secretion by binding to GLP-1 receptors (GLP1Rs) on pancreatic beta cells. GLP-1 mimetics are used in the clinic for the treatment of type 2 diabetes, but despite their therapeutic success, several clinical effects o...
Autores principales: | Biggs, Emma K., Liang, Lihuan, Naylor, Jacqueline, Madalli, Shimona, Collier, Rachel, Coghlan, Matthew P., Baker, David J., Hornigold, David C., Ravn, Peter, Reimann, Frank, Gribble, Fiona M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890879/ https://www.ncbi.nlm.nih.gov/pubmed/29119245 http://dx.doi.org/10.1007/s00125-017-4491-0 |
Ejemplares similares
-
Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake
por: Ouberai, Myriam M., et al.
Publicado: (2023) -
Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
por: Cork, Simon C., et al.
Publicado: (2015) -
The Human and
Mouse Islet Peptidome: Effects of Obesity
and Type 2 Diabetes, and Assessment of Intraislet Production of Glucagon-like
Peptide-1
por: Galvin, Sam G., et al.
Publicado: (2021) -
Mechanisms underlying glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion
por: Reimann, Frank, et al.
Publicado: (2016) -
Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly
por: Ouberai, Myriam M., et al.
Publicado: (2017)